Autism Spectrum DisordersMANAGENCT02797379
The Development of a Psychoeducational Tool to Manage Anxiety in People With Autism Spectrum Disorders
A study testing Psychoeducation in people with Autism Spectrum Disorders and Anxiety, run by King's College London at 2 sites in United Kingdom.
Trial summary
The purpose of this pilot intervention trial is to assess the efficacy of newly developed psychoeducation guides designed to manage anxiety in Autism Spectrum Disorder (ASD) by recruiting 30 participants with ASD and high levels of anxiety along with their parent/caregivers who both receive a version of the… Read more about this study
- Who is it for?
- Ages 8 to 25 years
- Conditions the study is for
- Autism Spectrum Disorders, Anxiety
- What is being tested?
- Psychoeducation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 35 participants
- Where
- 2 sitesUnited Kingdom
- Study dates
- 1 Sep 2016to 31 Aug 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 8 to 25 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- A diagnosis of ASD.
- Elevated levels of anxiety according to baseline questionnaire measure (Screen for Anxiety Related Disorders; SCARED)
- Have a parent/caregiver who is knowledgeable about participant's mental state and everyday activities and who can facilitate their use of the psychoeducation guide
- Mental age of 8 years or older, the lowest age recommended to complete the standardised measure of anxiety.
Who cannot join
- Participants or consultees, where relevant, who are unwilling to participate
- Participants who do not have a reasonable level of English. This is because a reasonable level of English will be required to engage with the guide, which is presently written in English and the questionnaires and/or interview questions about the guide. With younger participants with ASD using the materials, English should be the language used at home and school.
- Participants with any significant safeguarding concerns or involvement with court proceedings.
- Participants who are due to commence or have a major change in psychological or pharmacological treatment for their anxiety at a similar time to being given the psychoeducation guide.
Trial locations and contacts
2 sites in 1 country.
United Kingdom2 sites
South London and the Maudsley
London, SE5 8AF
Guy's and St Thomas' NHS trust
London
About this study
Official title: The Development of a Psychoeducation Tool to Manage Anxiety in People With Autism Spectrum Disorders: the Managing Anxiety iN Autism GuidE (MANAGE)
The purpose of this pilot intervention trial is to assess the efficacy of newly developed psychoeducation guides designed to manage anxiety in Autism Spectrum Disorder (ASD) by recruiting 30 participants with ASD and high levels of anxiety along with their parent/caregivers who both receive a version of the psychoeducation guide.
Read the detailed description
ASDs have a devastating impact on adaptive function; current UK lifetime costs of supporting a person with an ASD, along with the opportunity costs of lost productivity, are estimated at £0.8-1.2 million per year (Knapp, Romeo, \& Beecham, 2009). The impact of having an anxiety disorder has also been shown to affect an individual's quality of life and functioning over and above physical illness, major depression and socioeconomic factors (Stein et al., 2010). Around 40% of individuals with ASD will also have anxiety symptoms, and treatment for additional mental health problems is also costly. Early work using clinical therapies with individuals with ASD such as modified CBT indicate that the anxious symptoms which co-occur with ASD can be modified and improvements to the anxiety recorded although further work is needed. Therefore, focussing on interventions for individuals with ASD and anxiety may be very beneficial. However, not all individuals with ASD that also present with anxiety will require face to face therapy, therefore, psychoeducation could provide an effective and cost-effective way of improving mental health in ASD through self-help strategies. This could lead to improved outcomes for individuals and less burden on the clinical services supporting these families.
The intervention is focused on psychoeducation. Four psychoeducation guides will be available: parent/caregiver, adult with ASD, adolescent with ASD, and child with ASD. Participants and their parents/caregivers will be give guides to read in their own time over a 4 week period. The guides will be designed to improve participant's and their parent/caregiver's knowledge of anxiety in ASD. The guides introduce the concept of anxiety and how it presents in individuals with ASD, different anxiety triggers, strategies that can be used to manage anxiety, and an introduction to specific anxiety disorders. Level of detail, language and presentation of content will vary across the guides to be appropriate for the functioning level of the readers.
The aim of this study is to recruit 30 participants with autism spectrum disorder (ASD) and high levels of anxiety (aged 8-25 years) and their parent/caregiver into a pilot trial of a psychoeducation intervention. Participants will be recruited through clinical services in South London and the Maudsley (SLaM) and Guy's and St Thomas' (GSTT) NHS trusts through the patient consent to contact register (C4C) in SLaM and via referral from clinical care co-ordinators in the clinics in each trust. Additional participants may be recruited from non-clinical sources such as research recruitment lists held by autism charities or advertisements, including local newsletters, social media sites, emails or letters.
This is a pilot efficacy trial of newly developed psychoeducation guides employing a randomized, parallel-arm, intention to treat design with a 4 week intervention. Participant families will be randomly allocated (1:1) to either an immediate or a delayed start group to allow measurement of anxiety symptoms over a one month period with and without the psychoeducation guide. This design helps to control for the effects of attention (anxiety may show a large placebo response) while allowing all participants access to the intervention.
The aim is to improve participants' and their parent/caregivers' knowledge of the presentation of anxiety in ASD and their confidence in using simple strategies in its management. The primary outcome is improvement of participant and parent/caregiver understanding of the presentation and simple management strategies for anxiety in ASD. Secondary outcomes include improvement in anxiety symptoms and confidence in managing anxiety, feedback on acceptability, usefulness and appropriateness of the guide.
The trial analyses will be intention-to treat. Missing data will be imputed. The primary analysis will compare the groups randomized to immediate vs delayed treatment 4 weeks post randomisation when the immediate start group will have had the guide for 4 weeks and the delayed start group will have been on a "waiting list" for 4 weeks, this controls for attention and spontaneous improvement. The investigators will then check the two groups for comparability at pre-intervention time point (Time 1). If the two groups show similar baselines levels and magnitude of change in knowledge and symptom severity post intervention, they will be combined to gain a further estimate of the treatment effect. Both the knowledge/confidence measure and measure of anxiety symptoms, will be treated as continuous variables. Linear regression models will include baseline severity and randomisation group as predictors. The primary focus will be on parent-carer response but if sample sizes are sufficient, separate, parallel analyses will use data from individuals with ASD.
- Conditions
- Autism Spectrum Disorders, Anxiety
- Being tested
- Psychoeducation
- Keywords
- Psychoeducation, Self-help
- Medical subject headings
- Autism Spectrum Disorder, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PsychoeducationOther
Also called Self-help guide
The intervention is focused on psychoeducation. Four psychoeducation guides will be available: parent/caregiver, adult with ASD, adolescent with ASD, and child with ASD. The guides introduce the concept of anxiety and how it presents in individuals with ASD, different anxiety triggers, strategies that can be used to manage anxiety, and an introduction to specific anxiety disorders. Level of detail, language and presentation of content will vary across the guides to be appropriate for the functioning level of the readers.
| Study group | Role | What they receive |
|---|---|---|
| Immediate start | Other | This group receive the intervention (psychoeducation guide) immediately following baseline assessment and are assessed 4 and 8 weeks later. Receives: Other: Psychoeducation |
| Delayed start | Other | This group do not receive the intervention for 4 weeks. They are assessed after the wait period (4 weeks) and again after 4 weeks of having the intervention (psychoeducation guide) at week 8. Receives: Other: Psychoeducation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Knowledge about anxiety in ASD
The primary objective is to improve the participants' and their parent/caregivers' knowledge of the presentation of anxiety in ASD management from pre- to post-intervention. This will be measured after 4 weeks of using the psychoeducation guide (this will be 4 weeks post-randomisation for the immediate start group and 8 weeks post-randomisation for the delayed start group).
Measured: 4 weeks of using the guide
Secondary outcomes (2)
Anxiety symptoms
One secondary aim will be to determine whether use of the guide leads to a decrease in reported anxiety symptoms in the participant and their impact on everyday life. This will be measured pre and post intervention with the Screen for Anxiety Related Disorders.
Measured: 4 weeks of using the guide
Acceptability, usefulness and appropriateness of the guide
In providing the participant and/or their parent/caregiver with the psychoeducation guide the research team will also seek feedback on acceptability, usefulness and appropriateness of the guide for each participant. This will be measured using newly developed feedback questionnaire.
Measured: 4 weeks of using the guide
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jun 2016 (estimated)
- Study start1 Sep 2016
- Primary completion31 Aug 2017
- Study completion31 Aug 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Autism Spectrum DisordersStudies of the same condition, open and under way.
- More trials run by King's College LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 35 participants (actual)
Sponsor and investigators
- Lead sponsor
- King's College London
- Sponsor type
- University, hospital or other
- Collaborators
- South London and Maudsley NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust
- Responsible party
- Sponsor
- Investigators
- Emily Simonoff, MD, Principal investigator, King's College London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02797379
- Sponsor's protocol ID
- 200774
- Acronym
- MANAGE
- Status last verified
- Sep 2016
- First submitted
- 24 May 2016
- Last updated
- 13 Sep 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Sep 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Development of a Psychoeducation Tool to Manage Anxiety in People With Autism Spectrum Disorders: the Managing Anxiety iN Autism GuidE (MANAGE)
- ClinicalTrials.gov ID
- NCT02797379
- Acronym / sponsor ID
- MANAGE / 200774
- Conditions
- Autism Spectrum Disorders, Anxiety
- Keywords
- Psychoeducation, Self-help
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 35 participants (actual)
- Lead sponsor
- King's College LondonUniversity, hospital or other
- Collaborators
- South London and Maudsley NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust
- Study start
- 1 Sep 2016 (actual)
- Primary completion
- 31 Aug 2017 (actual)
- Study completion
- 31 Aug 2017 (actual)
- First posted
- 13 Jun 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this pilot intervention trial is to assess the efficacy of newly developed psychoeducation guides designed to manage anxiety in Autism Spectrum Disorder (ASD) by recruiting 30 participants with ASD and high levels of anxiety along with their parent/caregivers who both receive a version of the psychoeducation guide.
Detailed description
ASDs have a devastating impact on adaptive function; current UK lifetime costs of supporting a person with an ASD, along with the opportunity costs of lost productivity, are estimated at £0.8-1.2 million per year (Knapp, Romeo, \& Beecham, 2009). The impact of having an anxiety disorder has also been shown to affect an individual's quality of life and functioning over and above physical illness, major depression and socioeconomic factors (Stein et al., 2010). Around 40% of individuals with ASD will also have anxiety symptoms, and treatment for additional mental health problems is also costly. Early work using clinical therapies with individuals with ASD such as modified CBT indicate that the anxious symptoms which co-occur with ASD can be modified and improvements to the anxiety recorded although further work is needed. Therefore, focussing on interventions for individuals with ASD and anxiety may be very beneficial. However, not all individuals with ASD that also present with anxiety will require face to face therapy, therefore, psychoeducation could provide an effective and cost-effective way of improving mental health in ASD through self-help strategies. This could lead to improved outcomes for individuals and less burden on the clinical services supporting these families.
The intervention is focused on psychoeducation. Four psychoeducation guides will be available: parent/caregiver, adult with ASD, adolescent with ASD, and child with ASD. Participants and their parents/caregivers will be give guides to read in their own time over a 4 week period. The guides will be designed to improve participant's and their parent/caregiver's knowledge of anxiety in ASD. The guides introduce the concept of anxiety and how it presents in individuals with ASD, different anxiety triggers, strategies that can be used to manage anxiety, and an introduction to specific anxiety disorders. Level of detail, language and presentation of content will vary across the guides to be appropriate for the functioning level of the readers.
The aim of this study is to recruit 30 participants with autism spectrum disorder (ASD) and high levels of anxiety (aged 8-25 years) and their parent/caregiver into a pilot trial of a psychoeducation intervention. Participants will be recruited through clinical services in South London and the Maudsley (SLaM) and Guy's and St Thomas' (GSTT) NHS trusts through the patient consent to contact register (C4C) in SLaM and via referral from clinical care co-ordinators in the clinics in each trust. Additional participants may be recruited from non-clinical sources such as research recruitment lists held by autism charities or advertisements, including local newsletters, social media sites, emails or letters.
This is a pilot efficacy trial of newly developed psychoeducation guides employing a randomized, parallel-arm, intention to treat design with a 4 week intervention. Participant families will be randomly allocated (1:1) to either an immediate or a delayed start group to allow measurement of anxiety symptoms over a one month period with and without the psychoeducation guide. This design helps to control for the effects of attention (anxiety may show a large placebo response) while allowing all participants access to the intervention.
The aim is to improve participants' and their parent/caregivers' knowledge of the presentation of anxiety in ASD and their confidence in using simple strategies in its management. The primary outcome is improvement of participant and parent/caregiver understanding of the presentation and simple management strategies for anxiety in ASD. Secondary outcomes include improvement in anxiety symptoms and confidence in managing anxiety, feedback on acceptability, usefulness and appropriateness of the guide.
The trial analyses will be intention-to treat. Missing data will be imputed. The primary analysis will compare the groups randomized to immediate vs delayed treatment 4 weeks post randomisation when the immediate start group will have had the guide for 4 weeks and the delayed start group will have been on a "waiting list" for 4 weeks, this controls for attention and spontaneous improvement. The investigators will then check the two groups for comparability at pre-intervention time point (Time 1). If the two groups show similar baselines levels and magnitude of change in knowledge and symptom severity post intervention, they will be combined to gain a further estimate of the treatment effect. Both the knowledge/confidence measure and measure of anxiety symptoms, will be treated as continuous variables. Linear regression models will include baseline severity and randomisation group as predictors. The primary focus will be on parent-carer response but if sample sizes are sufficient, separate, parallel analyses will use data from individuals with ASD.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Immediate start | Other | Other: PsychoeducationThis group receive the intervention (psychoeducation guide) immediately following baseline assessment and are assessed 4 and 8 weeks later. |
| Delayed start | Other | Other: PsychoeducationThis group do not receive the intervention for 4 weeks. They are assessed after the wait period (4 weeks) and again after 4 weeks of having the intervention (psychoeducation guide) at week 8. |
Who may qualify
- Ages
- 8 to 25 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (4 listed)
- A diagnosis of ASD.
- Elevated levels of anxiety according to baseline questionnaire measure (Screen for Anxiety Related Disorders; SCARED)
- Have a parent/caregiver who is knowledgeable about participant's mental state and everyday activities and who can facilitate their use of the psychoeducation guide
- Mental age of 8 years or older, the lowest age recommended to complete the standardised measure of anxiety.
Key exclusion criteria (4 listed)
- Participants or consultees, where relevant, who are unwilling to participate
- Participants who do not have a reasonable level of English. This is because a reasonable level of English will be required to engage with the guide, which is presently written in English and the questionnaires and/or interview questions about the guide. With younger participants with ASD using the materials, English should be the language used at home and school.
- Participants with any significant safeguarding concerns or involvement with court proceedings.
- Participants who are due to commence or have a major change in psychological or pharmacological treatment for their anxiety at a similar time to being given the psychoeducation guide.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PsychoeducationAlso: Self-help guideThe intervention is focused on psychoeducation. Four psychoeducation guides will be available: parent/caregiver, adult with ASD, adolescent with ASD, and child with ASD. The guides introduce the concept of anxiety and how it presents in individuals with ASD, different anxiety triggers, strategies that can be used to manage anxiety, and an introduction to specific anxiety disorders. Level of detail, language and presentation of content will vary across the guides to be appropriate for the functioning level of the readers. | Other | Delayed start, Immediate start |
Primary outcome
Knowledge about anxiety in ASD
Time frame: 4 weeks of using the guide
The primary objective is to improve the participants' and their parent/caregivers' knowledge of the presentation of anxiety in ASD management from pre- to post-intervention. This will be measured after 4 weeks of using the psychoeducation guide (this will be 4 weeks post-randomisation for the immediate start group and 8 weeks post-randomisation for the delayed start group).
2 secondary outcomes
Anxiety symptoms
Time frame: 4 weeks of using the guide
Acceptability, usefulness and appropriateness of the guide
Time frame: 4 weeks of using the guide
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Sep 2019.
- Individual participant dataSharing planned: No
Related trials for Autism Spectrum Disorders
RecruitingPhase 1
Cannabidiol (CBD) in Adults With ASD
Autism Spectrum Disorder
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
Not yet recruiting
Sensory-integration Therapy Verses Augumented Reality-based Training in ASD
Autism Spectrum Disorder
Recruiting
Cumulative and Booster Effects of Multisession Prefrontal tDCS in ASD Adolescents
Transcranial Direct Current Stimulation, Autistic Spectrum Disorder
Not yet recruiting
"Family Resilience And Mind-body Enhancement" (FRAME): A Randomised Controlled Trial
Autism
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Emily Simonoff, MD principal investigator
King's College London
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Psychoeducation in people with Autism Spectrum Disorders and Anxiety, run by King's College London at 2 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Knowledge about anxiety in ASD (time frame: 4 weeks of using the guide). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Sep 2019.